Effect of a combined nutraceutical containing Orthosiphon stamineus effect on blood pressure and metabolic syndrome components in hypertensive dyslipidaemic patients: A randomized clinical trial

Complementary Therapies in Clinical Practice

Volumn 18, Issue 3, 2012, Pages 190-194

  Cicero, A F G ^a   De Sando, V ^a   Izzo, R ^b   Vasta, A ^b   Trimarco, A ^b   Borghi, C ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cardiovascular disease; Metabolic syndrome; Nutraceuticals; Ortosiphon; Risk

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; PLANT EXTRACT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG COMBINATION; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ORTHOSIPHON; PHYTOTHERAPY; PLANT LEAF; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIETARY SUPPLEMENTS; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ORTHOSIPHON; PHYTOTHERAPY; PLANT EXTRACTS; PLANT LEAVES; SINGLE-BLIND METHOD;

EID: 84863855961     PISSN: 17443881     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctcp.2012.02.002     Document Type: Article

References (32)

1. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
2. Bloch M.J., Basile J.N. Largest meta-analysis to date suggests that patients at risk for cardiovascular disease events derive benefit from antihypertensive therapy regardless of baseline blood pressure and to reduce vascular events, lowering blood pressure is more important than choice of antihypertensive drug class. J Clin Hypertens 2009, 11(12):743-745.
3. Mancia G., Grassi G. The New European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines. Ther Adv Cardiovasc Dis 2008, 2(1):5-12.
4. Chen J.M., Heran B.S., Wright J.M. Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. Cochrane Database Syst Rev 2009, (4). CD007187.
5. Elliott W.J. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens 2009, 11(7):376-382.
6. Ames R. Hyperlipidemia of diuretic therapy. Arch Mal Coeur Vaiss 1998, 91(Suppl.):23-27.
7. Zuchi C., Ambrosio G., Lüscher T.F., Landmesser U. Nutraceuticals in cardiovascular prevention: lessons from studies on endothelial function. Cardiovasc Ther 2010, 28(4):187-201.
8. Cicero A.F.G., Gerocarni B., Laghi L., Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysisof current available clinical trials. J Hum Hyper 2011, 25(7):425-436.
9. Houston M.C. Nutrition and nutraceutical supplements in the treatment of hypertension. Expert Rev Cardiovasc Ther 2010 Jun, 8(6):821-833.
10. Adam Y., Somchit M.N., Sulaiman M.R., Nasaruddin A.A., Zuraini A., Bustamam A.A., et al. Diuretic properties of Orthosiphon stamineus Benth. J Ethnopharmacol 2009, 124(1):154-158.
11. Yuliana N.D., Khatib A., Link-Struensee A.M., Ijzerman A.P., Rungkat-Zakaria F., Choi Y.H., et al. Adenosine A1 receptor binding activity of methoxy flavonoids from Orthosiphon stamineus. Planta Med 2009, 75(2):132-136.
12. Premgamone A., Sriboonlue P., Maskasem S., Ditsataporncharoen W., Jindawong B. Orthosiphon versus placebo in nephrolithiasis with multiple chronic complaints: a randomized control trial. Evid Based Complement Alternat Med 2009, 6(4):495-501.
13. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European Society of Cardiology (ESC); European Association for Cardiovascular Prevention and Rehabilitation (EACPR); Council on Cardiovascular Nursing; European Association for Study of Diabetes (EASD); International Diabetes Federation Europe (IDF-Europe); European Stroke Initiative (EUSI); International Society of Behavioural Medicine (ISBM); European Society of Hypertension (ESH); European Society of General Practice/Family Medicine (ESGP/FM/WONCA); European Heart Network (EHN).European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):E1-40.
14. Cicero A.F.G., Derosa G., Bove M., Imola F., Borghi C., Gaddi A.V. Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome. Curr Top Nutrac Res 2009, 7(3-4):121-126.
15. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. European Society of Hypertension; European Society of Cardiology. 2007 ESH-ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
16. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment Panel III). JAMA 2001, 285:2486-2497.
17. Palmieri L., Panico S., Vanuzzo D., Ferrario M., Pilotto L., Sega R., et al. Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. Ann Ist Super Sanita 2004, 40(4):393-399. Gruppo di Ricerca del Progetto CUORE.
18. Assmann G., Schulte H., Seedorf U. Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study. Int J Obes 2008, 32(Suppl. 2):S11-S16.
19. Cicero A.F.G., Derosa G., Bove M., Di Gregori V., Gaddi A.V., Borghi C. Effect of a sequential training program on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. Eur J Cardiovasc Prev Rehab 2009, 16(6):698-704.
20. Kelly R.B. Diet and exercise in the management of hyperlipidemia. Am Fam Physician 2010, 81(9):1097-1102.
21. Ray K.K., Seshasai S.R., Erqou S., Sever P., Jukema J.W., Ford I., et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010 Jun 28, 170(12):1024-1031.
22. Kraft K. Complementary/alternative medicine in the context of prevention of disease and maintenance of health. Prev Med 2009, 49(2-3):88-92.
23. Shukla S.K., Gupta S., Ojha S.K., Sharma S.B. Cardiovascular friendly natural products: a promising approach in the management of CVD. Nat Prod Res 2010, 24(9):873-898.
24. Nahas R. Complementary and alternative medicine approaches to blood pressure reduction: an evidence-based review. Can Fam Physician 2008, 54(11):1529-1533.
25. Nijjar P.S., Burke F.M., Bloesch A., Rader D.J. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol 2010, 4(4):248-258.
26. Affuso F., Ruvolo A., Micillo F., Saccà L., Fazio S. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 2010, 20(9):656-661.
27. Sinan Deveci O., Kabakci G., Okutucu S., Tulumen E., Aksoy H., Baris Kaya E., et al. The association between serum uric acid level and coronary artery disease. Int J Clin Pract 2010, 64(7):900-907.
28. Cicero A.F.G., Ertek S. Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription?. Med J Nutr Metab 2008, 1(2):85-93.
29. Izzo R., de Simone G., Giudice R., Chinali M., Trimarco V., De Luca N., et al. Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia. J Hypertens 2010, 28(7):1482-1487.
30. Correa V., Gus M., Fuchs F.D. Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects?. Expert Rev Cardiovasc Ther 2010, 8(6):775-779.
31. Zhang Q., Xiao X., Feng K., Wang T., Li W., Yuan T., et al. Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evid Based Complement Alternat Med 2011, pii: 924851.
32. Wassmann S., Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens Suppl 2006, 24(1):S15-S21.